IL239007B - Eribulin for use in the treatment of breast cancer - Google Patents
Eribulin for use in the treatment of breast cancerInfo
- Publication number
- IL239007B IL239007B IL239007A IL23900715A IL239007B IL 239007 B IL239007 B IL 239007B IL 239007 A IL239007 A IL 239007A IL 23900715 A IL23900715 A IL 23900715A IL 239007 B IL239007 B IL 239007B
- Authority
- IL
- Israel
- Prior art keywords
- eribulin
- treatment
- breast cancer
- breast
- cancer
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title 1
- 208000026310 Breast neoplasm Diseases 0.000 title 1
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 title 1
- 229960003649 eribulin Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261733238P | 2012-12-04 | 2012-12-04 | |
| US201361878204P | 2013-09-16 | 2013-09-16 | |
| PCT/IB2013/002911 WO2014087230A1 (en) | 2012-12-04 | 2013-12-04 | Use of eribulin in the treatment of breast cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL239007A0 IL239007A0 (en) | 2015-07-30 |
| IL239007B true IL239007B (en) | 2018-04-30 |
Family
ID=50031376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL239007A IL239007B (en) | 2012-12-04 | 2015-05-25 | Eribulin for use in the treatment of breast cancer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20140163095A1 (enExample) |
| EP (1) | EP2928464A1 (enExample) |
| JP (2) | JP6466339B2 (enExample) |
| KR (1) | KR20150090921A (enExample) |
| AU (2) | AU2013353745A1 (enExample) |
| BR (1) | BR112015012731A2 (enExample) |
| CA (1) | CA2892780A1 (enExample) |
| IL (1) | IL239007B (enExample) |
| MX (1) | MX2015007185A (enExample) |
| RU (1) | RU2689977C2 (enExample) |
| WO (1) | WO2014087230A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7982060B2 (en) | 2004-06-03 | 2011-07-19 | Eisai R&D Management Co., Ltd. | Intermediates for the preparation of analogs of Halichondrin B |
| MY160203A (en) | 2009-03-30 | 2017-02-28 | Eisai R&D Man Co Ltd | Liposome composition |
| US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| EP2928464A1 (en) * | 2012-12-04 | 2015-10-14 | Eisai R&D Management Co., Ltd. | Use of eribulin in the treatment of breast cancer |
| JP6644479B2 (ja) * | 2014-06-24 | 2020-02-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | がん治療のための併用療法としてのエリブリンとｓ−１（もしくは５−ｆｕ）の使用 |
| HRP20221047T1 (hr) | 2014-08-28 | 2022-11-11 | Eisai R&D Management Co., Ltd. | Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju |
| HUE064614T2 (hu) | 2015-02-25 | 2024-04-28 | Eisai R&D Man Co Ltd | Eljárás egy kinolin-származék keserû ízének elnyomására |
| EP3265122B1 (en) * | 2015-03-04 | 2022-05-04 | Merck Sharp & Dohme Corp. | Combination of pembrolizumab and eribulin for treating triple-negative breast cancer |
| BR112017027227B1 (pt) | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
| MX381976B (es) | 2015-08-20 | 2025-03-13 | Eisai R&D Man Co Ltd | Agente terapéutico contra tumores. |
| JP7015237B2 (ja) | 2016-04-28 | 2022-02-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍の成長を抑制する方法 |
| KR102539920B1 (ko) | 2017-02-08 | 2023-06-05 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 종양-치료용 약제학적 조성물 |
| BR112019017047A2 (pt) * | 2017-02-20 | 2020-04-28 | Polyphor Ag | combinações farmacêuticas para tratar câncer |
| RU2019134940A (ru) | 2017-05-16 | 2021-06-16 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Лечение гепатоцеллюлярной карциномы |
| WO2019017497A1 (en) * | 2017-07-21 | 2019-01-24 | Eisai R&D Management Co., Ltd. | USE OF CYCLIN-DEPENDENT KINASE ERIBULINE AND INHIBITORS IN THE TREATMENT OF CANCER |
| US11419856B2 (en) | 2017-11-20 | 2022-08-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| US20210030735A1 (en) * | 2018-02-05 | 2021-02-04 | Tesaro, Inc. | Pediatric niraparib formulations and pediatric treatment methods |
| WO2019173843A1 (en) * | 2018-03-09 | 2019-09-12 | The Regents Of The University Of California | Combination treatment of chemoresistant cancers |
| EP3877422A4 (en) * | 2018-11-09 | 2022-08-24 | G1 Therapeutics, Inc. | Therapeutic regimens for treatment of cancer using eribulin and selective cdk4/6 inhibitor combinations |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| WO2025106586A1 (en) * | 2023-11-13 | 2025-05-22 | Luxvitae Therapeutics Inc. | Macrocyclic ketone compounds and applications thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1087960T3 (da) | 1998-06-17 | 2011-06-14 | Eisai R&D Man Co Ltd | Makrocykliske analoger og fremgangsmåder til deres anvendelse og fremstilling |
| US6653341B1 (en) | 1998-06-17 | 2003-11-25 | Eisai Co., Ltd. | Methods and compositions for use in treating cancer |
| US7982060B2 (en) | 2004-06-03 | 2011-07-19 | Eisai R&D Management Co., Ltd. | Intermediates for the preparation of analogs of Halichondrin B |
| CN103285395A (zh) * | 2005-02-18 | 2013-09-11 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| WO2007107305A2 (en) * | 2006-03-22 | 2007-09-27 | Medigene Ag | Treatment of triple receptor negative breast cancer |
| WO2009046308A1 (en) | 2007-10-03 | 2009-04-09 | Eisai R & D Management Co., Ltd. | Intermediates and methods for the synthesis of halichondrin b analogs |
| SG189739A1 (en) | 2008-04-04 | 2013-05-31 | Eisai R&D Man Co Ltd | Halichondrin b analogs |
| EP2528914B1 (en) | 2010-01-26 | 2014-06-11 | Eisai R&D Management Co., Ltd. | Furo[3,2-b]pyrane derivatives useful in the synthesis of halichondrin b analogs |
| SG193489A1 (en) * | 2011-03-18 | 2013-10-30 | Eisai R&D Man Co Ltd | Methods and compositions for predicting response to eribulin |
| EP2928464A1 (en) * | 2012-12-04 | 2015-10-14 | Eisai R&D Management Co., Ltd. | Use of eribulin in the treatment of breast cancer |
-
2013
- 2013-12-04 EP EP13826752.1A patent/EP2928464A1/en not_active Withdrawn
- 2013-12-04 JP JP2015544557A patent/JP6466339B2/ja active Active
- 2013-12-04 US US14/096,827 patent/US20140163095A1/en not_active Abandoned
- 2013-12-04 KR KR1020157017971A patent/KR20150090921A/ko not_active Ceased
- 2013-12-04 RU RU2015126539A patent/RU2689977C2/ru active
- 2013-12-04 MX MX2015007185A patent/MX2015007185A/es unknown
- 2013-12-04 BR BR112015012731A patent/BR112015012731A2/pt not_active Application Discontinuation
- 2013-12-04 AU AU2013353745A patent/AU2013353745A1/en not_active Abandoned
- 2013-12-04 CA CA2892780A patent/CA2892780A1/en not_active Abandoned
- 2013-12-04 WO PCT/IB2013/002911 patent/WO2014087230A1/en not_active Ceased
-
2015
- 2015-05-25 IL IL239007A patent/IL239007B/en active IP Right Grant
-
2018
- 2018-08-09 AU AU2018214086A patent/AU2018214086B2/en not_active Withdrawn - After Issue
-
2019
- 2019-01-09 JP JP2019002177A patent/JP6678783B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019089776A (ja) | 2019-06-13 |
| BR112015012731A2 (pt) | 2017-07-11 |
| AU2018214086B2 (en) | 2020-07-09 |
| JP6678783B2 (ja) | 2020-04-08 |
| JP6466339B2 (ja) | 2019-02-06 |
| CA2892780A1 (en) | 2014-06-12 |
| RU2015126539A (ru) | 2017-01-13 |
| JP2016501213A (ja) | 2016-01-18 |
| MX2015007185A (es) | 2017-09-05 |
| AU2013353745A1 (en) | 2015-06-11 |
| US20140163095A1 (en) | 2014-06-12 |
| RU2689977C2 (ru) | 2019-05-30 |
| IL239007A0 (en) | 2015-07-30 |
| WO2014087230A1 (en) | 2014-06-12 |
| KR20150090921A (ko) | 2015-08-06 |
| EP2928464A1 (en) | 2015-10-14 |
| AU2018214086A1 (en) | 2018-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL239007B (en) | Eribulin for use in the treatment of breast cancer | |
| GB2495841B (en) | Phytocannabinoids for use in the treatment of breast cancer | |
| GB201115711D0 (en) | Phyto-cannabinoids for use in the treatment of cancer | |
| IL237558A0 (en) | Methods for treating locally advanced breast cancer | |
| IL238400A (en) | Triazulophyrazines as brd4 inhibitors for use in cancer treatment | |
| GB2516814B (en) | Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer | |
| IL242386B (en) | Use of Aribolin and Lavetinib as a combination therapy for cancer treatment | |
| IL238249B (en) | Cancer treatment | |
| EP2751267A4 (en) | METHOD FOR THE TREATMENT OF BREAST CANCER | |
| SMT201900024T1 (it) | Terapia combinata per il trattamento di cancro | |
| IL230698A0 (en) | Use of preparations containing crizotinib to treat cancer | |
| IL238116B (en) | A process for preparing compounds for use in the treatment of cancer | |
| EP2903644A4 (en) | TREATMENT OF CANCER | |
| GB201217892D0 (en) | Treatment of cancer | |
| IL238453A0 (en) | Trans-clomiphene for use in cancer treatment | |
| SI2892925T1 (sl) | Kombinacijsko zdravljenje raka | |
| LT2872176T (lt) | Karboranilporfirinai, skirti naudoti vėžio gydymui | |
| PL2855475T3 (pl) | Alfa-karboliny do leczenia nowotworu | |
| GB201217890D0 (en) | Treatment of cancer | |
| IL233495A0 (en) | Combination for cancer treatment | |
| GB201322958D0 (en) | Uses of oligouronates in cancer treatment | |
| GB201222950D0 (en) | Combination treatment of cancer | |
| GB201222949D0 (en) | Combination Treatment of Cancer | |
| GB201200262D0 (en) | Therapy of breast cancer | |
| GB201208296D0 (en) | Treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |